RT Journal Article
SR Electronic
T1 Convalescent Plasma to Treat COVID-19: Chinese Strategy and Experiences
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.07.20056440
DO 10.1101/2020.04.07.20056440
A1 Pei, Shiyao
A1 Yuan, Xi
A1 Zhang, Zhimin
A1 Yao, Run
A1 Xie, Yubin
A1 Shen, Minxue
A1 Li, Bijuan
A1 Chen, Xiang
A1 Yin, Mingzhu
YR 2020
UL http://medrxiv.org/content/early/2020/04/11/2020.04.07.20056440.abstract
AB The COVID-19 is currently spreading around the world, which has posed significant threats to global health and economy. Convalescent plasma is confirmed effective against the novel corona virus in preliminary studies. In this paper, we first described the therapeutic schedule, antibody detection method, indications, contraindications of the convalescent plasmas, and reported the operability of the treatment by case study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data referred in the manuscript is available